Dalbavancin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dalbavancin
Dalbavancin.png
Clinical data
Legal status ?
Routes Intravenous
Identifiers
CAS number 171500-79-1 YesY
ATC code J01XA04
PubChem CID 16134410
ChemSpider 23340937 N
UNII 808UI9MS5K N
ChEMBL CHEMBL527063 N
Chemical data
Formula C88H100Cl2N10O28 
Mol. mass 1755.634 g/mol
 N (what is this?)  (verify)

Dalbavancin (INN, trade name Zeven) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[1]

Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.[2]

It possesses in vitro activity against a variety of Gram-positive pathogens[3][4] including MRSA and MRSE.[5] It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[6]

Clinical progress[edit]

Dalbavancin has undergone a phase III clinical trial for adults with complicated skin infections, but in Dec 2007 the FDA said more data was needed before approval.[6] On September 9, 2008, Pfizer announced that it will withdraw all marketing applications in order to conduct another Phase 3 clinical trial.[7] Durata Therapeutics acquired the rights to dalbavancin in December 2009 and has initiated two new Phase III clinical trials for treatment of acute bacterial skin and skin structure infections.[8] Preliminary results in Dec 2012 looked good.[9]

References and notes[edit]

  1. ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
  2. ^ Scheinfeld NS. (May 2006). "Dalbavancin: A review for dermatologists.". Dermatology Online Journal 12 (6). PMID 17083861. 
  3. ^ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMC 1890846. PMID 17362476. 
  4. ^ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci 21 (1): 78–88. PMID 18166524. 
  5. ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
  6. ^ a b UPDATE 1-Pfizer says US FDA wants more data on antibiotic. Dec 2007
  7. ^ "Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial" (Press release). Pfizer Inc. 2008-09-09. Retrieved 2008-09-11. 
  8. ^ Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development - October 05, 2011.
  9. ^ Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI